Radiopharm Theranostics Reports Positive Early Results Across Four Lead Clinical Programs
Reuters
Oct 20, 2025
<a href="https://laohu8.com/S/RDPTF">Radiopharm Theranostics</a> Reports Positive Early Results Across Four Lead Clinical Programs
Radiopharm Theranostics Ltd. has provided updates on its clinical pipeline, reporting progress across four lead programs in oncology radiopharmaceuticals. Preliminary data from the first three patients in the Phase 2b imaging clinical trial of RAD 101 demonstrated uptake in brain metastases from solid tumors, confirming proof-of-concept. Topline results from this trial are expected by the first half of 2026. In the Phase 1 clinical trial of RAD 202 (HER2), the first patient cohort showed higher than expected tumor uptake, with full enrollment of the second cohort and data anticipated by the end of 2025. The Phase 1 study of RAD 204 (PDL-1) reported promising tumor uptake, and two out of three patients at the first dose level achieved stable disease. Additionally, data from the Phase 1 study of RAD 301 have supported the advancement to a Phase 2 imaging trial in patients with loco-regional pancreatic cancer. The company also announced plans to initiate Phase 1 trials for RV01 and RAD402, two monoclonal antibody assets, by year-end, expanding its clinical portfolio to include four therapeutic candidates and two imaging agents by December 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001133899-en) on October 20, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.